{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Control+Form+6&page=5",
    "query": {
      "intervention": "Placebo Control Form 6",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 241,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Control+Form+6&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Control+Form+6&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T00:09:51.077Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07169279",
      "title": "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib is provided as a single dose of minitablets for oral administration",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib is provided as sprinkle capsules for daily oral administration",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "32 Months",
        "sex": "ALL",
        "summary": "0 Years to 32 Months"
      },
      "enrollment_count": 77,
      "start_date": "2025-11-19",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Baltimore, Maryland • Madison, Wisconsin",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07169279"
    },
    {
      "nct_id": "NCT01282684",
      "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PLX5622",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Plexxikon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2011-01",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2015-03-30",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01282684"
    },
    {
      "nct_id": "NCT03770728",
      "title": "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Efpeglenatide SAR439977",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Metformin alone or in combination with SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "2019-08-01",
      "completion_date": "2020-12-27",
      "has_results": true,
      "last_update_posted_date": "2021-12-02",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03770728"
    },
    {
      "nct_id": "NCT02968446",
      "title": "Effect of Vitamin D After Application With Valchlor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Skin Irritation"
      ],
      "interventions": [
        {
          "name": "4 placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "4 Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Valchlor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-11-17",
      "completion_date": "2018-10-01",
      "has_results": false,
      "last_update_posted_date": "2021-12-23",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02968446"
    },
    {
      "nct_id": "NCT02131194",
      "title": "The Post-Vitrectomy Lenstatin™ Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataract, Nuclear Progressive"
      ],
      "interventions": [
        {
          "name": "Lenstatin",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Lenstatin LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-06",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 1,
      "location_summary": "Wilmington, North Carolina",
      "locations": [
        {
          "city": "Wilmington",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02131194"
    },
    {
      "nct_id": "NCT03387137",
      "title": "Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "RSV 6120/∆NS2/1030s",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "60 Months",
        "sex": "ALL",
        "summary": "6 Months to 60 Months"
      },
      "enrollment_count": 45,
      "start_date": "2017-10-13",
      "completion_date": "2021-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03387137"
    },
    {
      "nct_id": "NCT06590337",
      "title": "Radicle Spark for Men 24: A Study of Health and Wellness Products on Sexual Health and Related Health Outcomes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sexual Satisfaction",
        "Sexual Function"
      ],
      "interventions": [
        {
          "name": "Spark Placebo Control Form 1",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Spark Active Study Product 1.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Spark Placebo Control Form 2",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Spark Active Study Product 2.1 Usage",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Radicle Science",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "105 Years",
        "sex": "MALE",
        "summary": "21 Years to 105 Years · Male only"
      },
      "enrollment_count": 1202,
      "start_date": "2024-10-07",
      "completion_date": "2025-01-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 1,
      "location_summary": "Del Mar, California",
      "locations": [
        {
          "city": "Del Mar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06590337"
    },
    {
      "nct_id": "NCT02315703",
      "title": "Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-Mosaic",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp140 DP Low-dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp140 DP High-dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 393,
      "start_date": "2014-12-22",
      "completion_date": "2022-03-28",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02315703"
    },
    {
      "nct_id": "NCT01484275",
      "title": "A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-risk Smoldering Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Siltuximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2012-03-01",
      "completion_date": "2019-08-21",
      "has_results": true,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Kittanning",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484275"
    },
    {
      "nct_id": "NCT01893554",
      "title": "Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "RSV ΔNS2 Δ1313 I1314L Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "4 Months",
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "4 Months to 59 Months"
      },
      "enrollment_count": 88,
      "start_date": "2013-06-01",
      "completion_date": "2023-04-26",
      "has_results": false,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-10-31T00:09:51.077Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Laurel, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Laurel",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01893554"
    }
  ]
}